Debating growth hormone peptide protocols with my clinical team. Goal: boost GH/IGF-1 for anabolism, recovery, and sleep while testing a compound interaction hypothesis.

The hypothesis: Tirzepatide (GLP-1/GIP agonist) raises resting HR, disrupts sleep, and crushes appetite. CJC-1295 (GHRH analog) can worsen insulin resistance. Stack them and theoretically the negatives cancel—CJC's slow-wave sleep enhancement counters tirzepatide's sleep disruption, while tirzepatide's insulin sensitization offsets CJC's resistance effects.

Two protocol options:

CJC-1295 with DAC (Drug Affinity Complex): Long-acting, 1x weekly injection, active 6-8 days. Clinical trial validated. Single dose raises GH 2-10x, IGF-1 1.5-3x. Preserves pulsatility under continuous stimulation. Downside: locked in for a week if side effects hit, harder to titrate.

CJC-1295 no-DAC + ipamorelin: Short-acting daily pre-bed injection, clears in 30 min. Ipamorelin hits ghrelin pathway for pulse frequency boost on top of CJC's amplitude increase. No cortisol/prolactin spike. Most clinicians prescribe this, massive community adoption. Downside: less clinical trial data, daily pins, more anecdotal.

Considering:

- Start DAC at 2.4mg half-dose, escalate to 4.8mg weekly if tolerated

- If not tolerable, switch to no-DAC + ipamorelin (100mcg → 200-300mcg daily)

- Or run head-to-head: 2 weeks DAC vs 2 weeks no-DAC + ipamorelin

Tracking stack: GH, IGF-1, cortisol, CGM, real-time core temp, RHR, overnight HRV (rMSSD), HOMA-IR, sleep architecture, subjective recovery.

Tension: DAC has the published data (purist choice), but no-DAC + ipamorelin is what thousands actually run in practice (pragmatic, socially relevant data generation).

Thoughts on protocol selection?